bioAffinity Technologies (BIAF) Maxim Group’s 2024 Healthcare Virtual Summit summary

Conference overview

• The event featured over 85 healthcare companies, with a focus on innovative diagnostics and therapeutics.

• Presentations included company overviews, product pipelines, and commercial strategies.

• Keynote speakers discussed market trends and the importance of early cancer detection.

• Investor Q&A sessions provided insights into company growth plans and technology platforms.

Product innovation and clinical performance

• A new non-molecular, flow cytometry-based test for early lung cancer detection was highlighted.

• The test is patient-friendly, allowing at-home sample collection and rapid results.

• Demonstrated high sensitivity (92%) and specificity (87%) for small pulmonary nodules, with a 99% negative predictive value.

• The technology is positioned as a platform for future tests in other indications.

Commercialization and market expansion

• The test is currently reimbursed by Medicare, Medicaid, and private insurers, supporting accelerated growth.

• Recently added to the Federal Supply Schedule, enabling access for VA and military physicians.

• Initial commercial rollout focused on Texas, with expansion plans targeting key states and nationwide VA systems.

• Word-of-mouth and physician advocacy are driving adoption beyond the initial market.